Primary Hyperaldosteronism and Ischemia-reperfusion Injury — PHA-FMD  

Primary Hyperaldosteronism Clinical Trial

Official title: Primary Hyperaldosteronism and Endothelial Ischemia-reperfusion Injury

Status Completed

Clinical Trial Summary

Patients with primary hyperaldosteronism experience more cardiovascular events compared to patients with primary hypertension, independent of the blood pressure level.

In this research we hypothesize that patients with primary hyperaldosteronism are more susceptible to ischemia-reperfusion injury.

Clinical Trial Description

Patients with PHA have an increased risk of cardiovascular events, independent of blood pressure level. Also in patients suffering a myocardial infarction, circulating aldosterone levels are associated with increased mortality. In animal models of myocardial infarction, the administration of exogenous aldosterone increased infarct size, although other studies did not report this effect. In similar models, antagonists of the mineralocorticoid receptor (MR) reduced infarct size, which was completely abolished in ecto-5'-nucleotidase (CD73, the enzyme that catalyses extracellular formation of the endogenous nucleoside adenosine) and adenosine receptor knock-out mice. Therefore, we hypothesize that patients with PHA have an increased susceptibility for ischemia-reperfusion (IR)-injury due to down-regulation of the enzyme CD73. We will use the reduction in brachial flow-mediated dilation (FMD) by forearm IR as a well-validated endpoint for (endothelial) IR-injury. ;

Related Conditions & MeSH terms

• Hyperaldosteronism
• Ischemia
• Primary Hyperaldosteronism
• Reperfusion Injury

• NCT number: NCT01978132
• Study type: Interventional
• Source: Radboud University
• Status: Completed
• Phase: N/A
• Start date: November 2013
• Completion date: July 1, 2017